Search
Colistin
go.drugbank.com/drugs/DB00803ApprovedInvestigationalIt is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. … Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.
Synonyms: Polymyxin EMixtures: Coly-Mycin S, Coly-Mycin SDulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigationalDulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … therapy to diet and exercise in the management of 2 diabetes (T2DM).
Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsProducts: TRULICITY® 1.5 MG/0.5 ML, TRULICITY® 0.75 MG/0.5 MLTetracaine
go.drugbank.com/drugs/DB09085ApprovedInvestigationalVet approvedTetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.
Synonyms: 2-(dimethylamino)ethyl 4-(butylamino)benzoate, 2-(Dimethylamino)ethyl p-(butylamino)benzoateMixtures: Ndc 72934- 5010-4 Benzocaine 20% / Lidocaine 8% / Tetracaine 4%., Pliaglis 70 mg/g + 70 mg/g CremeAsfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalby the U.S. … Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved
Products: STRENSİQ 18 MG/0.45 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET, STRENSİQ 28 MG/0.7 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADETGlucagon
go.drugbank.com/drugs/DB00040ApprovedInvestigationalGlucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.
Categories: Sex Hormones and InsulinsProducts: GLUCAGEN FOR INJECTION 1 mg/ml, Gvoke PFS 1 mg Pre-filled SyringeMicafungin
go.drugbank.com/drugs/DB01141ApprovedInvestigationalIt belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
Products: MYACIT 50 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 1 ADET, MSFUNGİN 50 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 1 ADETBacitracin
go.drugbank.com/drugs/DB00626ApprovedInvestigationalVet approvedBacitracin is a combination of at least 9 bacitracins.[A955,A181952] 60-80% of commercially prepared bacitracin is bacitracin A. … [A181952] The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy.
Synonyms: Bacitracin AMixtures: THIOCILLINE 500 IU/G + 5 MG/G DERİ MERHEMİ, 30 G, THIOCILLINE 500 IU/G + 5 MG/G GÖZ MERHEMİ, 5 GRCanakinumab
go.drugbank.com/drugs/DB06168ApprovedInvestigationalCanakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. … It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated.
Categories: Interleukin-1 BlockersProducts: ILARIS® SOLUCIÓN INYECTABLE 150 MG/ ML, İLARİS 150 MG/ML ENJEKSİYONLUK ÇÖZELTİ, 1 ADETVenetoclax
go.drugbank.com/drugs/DB11581ApprovedInvestigationalVenetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. … Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process [A18565], [A18566].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide, 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamideDenosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigational; Both biosimilars also received marketing authorization in the EU in May 2024. … Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia®
Products: XGEVA® 120 MG/1.7 ML, XGEVA 120 MG SC. ENJEKSIYONLUK COZELTI ICEREN FLAKON, 4 ADET